Citations

Clear

49 citation(s) found for "Thornton, S".

Placental senescence pathophysiology is shared between peripartum cardiomyopathy and preeclampsia in mouse and human
Roh, Jason D. , Castro, Claire , Yu, Andy, Rana, Sarosh , Shahul, Sajid , Gray, Kathryn J. , Honigberg, Michael C. , Ricke‐Hoch, Melanie , Iwamoto, Yoshiko , Yeri, Ashish, Guerra, Justin Ralph Baldovino , Hobson, Ryan , Chaudhari, Vinita , Chang, Bliss , Sarma, Amy , Lerchenmüller, Carolin , Sayed, Zeina R. Al , Verdugo, Carmen Diaz , Xia, Peng , Skarbianskis, Niv, Zeisel, Amit , Kirkland, James L. , Gorcsan, John , Damp, Julie B., Hanley‐Yanez, Karen , McNamara, Dennis M. , Investigators, for the IPAC, Rosenzweig, Anthony , Fett, James D., Pisarcik, Jessica, McTiernan, Charles F. , Alharethi, Rami , Rasmusson, Kismet, Brunisholz, Kim , Butler, Amy L., Budge, D., Kfoury, Abdallah G., Horne, Benjamin D. , Tuinei, Joe, Brown, Heather , Naftilan, Allen J., Russell, Jill , Freehardt, Darla, Hsich, Eileen , Oblak, Cynthia, Ewald, Greg, Whitehead, Donna, Flanagan, Jean, Platts, Anne, Mullin, Stephanie, Givertz, Michael M. , Anello, Mary Susan, Booth, David R. , Sandlin, Tiffany, Wijesiri, Wendy, Blauwet, Lori A., Brunner, Joann, Phelps, Mary, Kempf, Ruth, Modi, Kalgi , Norwood, Tracy, Griza, Decebal Sorin, Adams, Patricia L., Thohan, Vinay , Wesley-Farrington, Deborah, Soots, Sandra, Sheppard, Richard , Lapointe, Nathalie, Nathaniel, Heather, Kealey, Angela, Semigran, Marc J., Daher, Maureen, Silber, David, Popjes, Eric , Frey, Patricia, Nicklas, Todd, Alexis, Jeffrey D. , Caufield, Lori, Thornton, John W., Gentry, Mindy, Robinson, V.J. , Sharma, Gyanendra K. , Holloway, Joan, Powell, Maria, Markham, David W. , Fernandez, Lynn, Gimovsky, Martin L., Hochbaum, Natalia, Patel, Bharati Kadamb , Adams, Laura , Ramani, Gautam , Robinson, Shawn , Fisher, Stacy D. , Marshall, Joanne, Haythe, Jennifer , Mancini, Donna , Bijou, Rachel, Marks, Marybeth, Arango, Henry, Bolos, Mariana, Mather, Paul , Rubin, Sharon, Bonita, Raphael , Eberwine, Susan, Skopicki, Hal A. , Stergiopoulos, Kathleen , McCathy-Santoro, Ellen, Intravaia, Jennifer, Maas, Elizabeth W., Safirstein, Jordan, Martinez, Nancy , Corpoin, Christine, Hesari, Donna, Chaparro, Sandra , Hudson, Laura J., Ghali, Jalal K. , Injic, Zora, Wittstein, Ilan S. , Kitchen, Robert , Guerra, Justin Baldovino , Chaudhari, Vinita , Chang, Bliss , Sarma, Amy , Al Sayed, Zeina R , Diaz Verdugo, Carmen , Xia, Peng , Zeisel, Amit , Bauersachs, Johann , Kirkland, James L , Karumanchi, S Ananth , Gorcsan, John , Sugahara, Masataka , Hanley-Yanez, Karen , Ellinor, Patrick T , Arany, Zoltan Pierre , McNamara, Dennis M , Rosenzweig, Anthony , Honigberg, Michael C , Castro, Claire , Karumanchi, S. Ananth , Ellinor, Patrick T. , Investigators, for the IPAC, Hilfiker‐Kleiner, Denise , Schelbert, Erik B. , Butler, Amy, Elkayam, Uri , Caro, Jorge , Rajagopalan, Navin , Booth, David, Cooper, Leslie T. , Briller, Joan Ellen , Felker, G. Michael , Kociol, Robb D. , Adams, Patricia, Wells, Gretchen , Michel, Caroline, Boehmer, John , Holloway, Joan, Powell, Maria, Drazner, Mark H. , Zucker, Mark Jay , Baran, David A. , Patel, Bharati, Gottlieb, Stephen S. , Farr, Maryjane , Bozkurt, Biykem , Maas, Elizabeth, Kleet, Audrey

Mayo Clinic

Science Translational Medicine | April 17, 2024 | Volume: 16 | Issue: 743 | Pages: No page available

10.1126/scitranslmed.adi0077 | PMID 38630848 Get It

Peripartum cardiomyopathy (PPCM) is an idiopathic form of pregnancy-induced heart failure associated with preeclampsia. Circulating factors in late pregnancy are thought to contribute to both diseases, suggesting a common underlying pathophysiological process. However, what drives this process remains unclear. Using serum proteomics, we identified the senescence-associated secretory phenotype (SASP), a marker of cellular senescence associated with biological aging, as the most highly up-regulated pathway in young women with PPCM or preeclampsia. Placentas from women with preeclampsia displayed multiple markers of amplified senescence and tissue aging, as well as overall increased gene expression of 28 circulating proteins that contributed to SASP pathway enrichment in serum samples from patients with preeclampsia or PPCM. The most highly expressed placental SASP factor, activin A, was associated with cardiac dysfunction or heart failure severity in women with preeclampsia or PPCM. In a murine model of PPCM induced by cardiomyocyte-specific deletion of the gene encoding peroxisome proliferator–activated receptor γ coactivator-1α, inhibiting activin A signaling in the early postpartum period with a monoclonal antibody to the activin type II receptor improved heart function. In addition, attenuating placental senescence with the senolytic compound fisetin in late pregnancy improved cardiac function in these animals. These findings link senescence biology to cardiac dysfunction in pregnancy and help to elucidate the pathogenesis underlying cardiovascular diseases of pregnancy.
Multiple System Atrophy Presenting as Motor Neuron Disease (P6.069)
Jones, Lauren Thornton, Nelson, Renée, Bower, James H., Matsumoto, Joseph Y., Sandroni, Paola , Benarroch, Eduardo E. , Suarez, Mariana, Low, Phillip A. , Nelson, Renee, Singer, Wolfgang , Coon, Elizabeth A.

Mayo Clinic

Neurology | December 7, 2023 | Volume: 90 | Issue: 15_supplement | Pages: No page available

10.1212/wnl.90.15_supplement.p6.069 Get It

Major Publications in the Critical Care Pharmacotherapy Literature: 2022
Gurnani, Payal K. , Barlow, Brooke , Busse, Laurence W. , Ford, Jenna , Gibson, Gabrielle , Lee, Jennifer , Rivosecchi, Ryan , Spezzano, Katherine , Thornton, Nathan, Vallabhajosyula, Saraschandra , Wieruszewski, Patrick M. , Vallabhajosyula, Saraschandra , Wieruszewski, Patrick M , Boling, Bryan , Díaz‐Gómez, José L. , Khanna, Ashish K. , Thornton, Nathan, Witenko, Corey J.

Mayo Clinic

Critical Care Explorations | September 25, 2023 | Volume: 5 | Issue: 10 | Pages: e0981

10.1097/cce.0000000000000981 | PMID 37753239 Get It

OBJECTIVES: A number of trials related to critical care pharmacotherapy were published in 2022. We aimed to summarize the most influential publications related to the pharmacotherapeutic care of critically ill patients in 2022. DATA SOURCES: PubMed/Medical Literature Analysis and Retrieval System Online and the Clinical Pharmacy and Pharmacology Pharmacotherapy Literature Update. STUDY SELECTION: Randomized controlled trials, prospective studies, or systematic review/meta-analyses of adult critically ill patients assessing a pharmacotherapeutic intervention and reporting clinical endpoints published between January 1, 2022, and December 31, 2022, were included in this article. DATA EXTRACTION: Articles from a systematic search and the Clinical Pharmacy and Pharmacology Pharmacotherapy Literature Update were included and stratified into clinical domains based upon consistent themes. Consensus was obtained on the most influential publication within each clinical domain utilizing an a priori defined three-round modified Delphi process with the following considerations: 1) overall contribution to scientific knowledge and 2) novelty to the literature. DATA SYNTHESIS: The systematic search and Clinical Pharmacy and Pharmacology Pharmacotherapy Literature Update yielded a total of 704 articles, of which 660 were excluded. The remaining 44 articles were stratified into the following clinical domains: emergency/neurology, cardiovascular, gastroenterology/fluids/nutrition, hematology, infectious diseases/immunomodulation, and endocrine/metabolic. The final article selected from each clinical domain was summarized following a three-round modified Delphi process and included three randomized controlled trials and three systematic review/meta-analyses. Article topics summarized included dexmedetomidine versus other sedatives during mechanical ventilation, beta-blocker treatment in the critically ill, restriction of IV fluids in septic shock, venous thromboembolism prophylaxis in critically ill adults, duration of antibiotic therapy for Pseudomonas aeruginosa ventilator-associated pneumonia, and low-dose methylprednisolone treatment in severe community-acquired pneumonia. CONCLUSIONS: This concise review provides a perspective on articles published in 2022 that are relevant to the pharmacotherapeutic care of critically ill patients and their potential impact on clinical practice.
The effect of plasma exchange on serum levels of lacosamide: A case report
Peters, Bradley J. , Brown, Andrew E. , Thornton, Nathaniel M, Chalmers, Sarah , Chalmers, Sarah J, Thornton, Nathaniel M, Winters, Jeffrey L.

Mayo Clinic

American Journal of Health-System Pharmacy | September 15, 2023 | Volume: 80 | Issue: 24 | Pages: 1781-1786

10.1093/ajhp/zxad224 | PMID 37712141 Get It

Abstract Purpose We describe the case of a 22-year-old male who developed thyroid storm necessitating therapeutic plasma exchange (TPE). The patient’s past medical history was complicated by epilepsy, for which he took lacosamide. Little evidence was available to guide lacosamide dosing during TPE. Because of an exacerbation of the patient’s underlying epilepsy in the context of the thyroid storm, we conducted therapeutic medication monitoring of lacosamide concentrations to guide management. Summary We arranged for measurement of the lacosamide concentration immediately before TPE (5.1 μg/mL) and 2.5 hours after the initial measurement (3.4 μg/mL) to determine the amount of lacosamide removed by TPE. Utilizing population pharmacokinetic parameters, we calculated the expected concentration and compared this to the measured concentration. The difference between these values was used to determine the percentage removed via TPE compared to the expected post-TPE concentration. We found that one TPE session removed an additional 20% of serum lacosamide. Conclusion TPE appeared to remove an additional 20% of lacosamide when compared to the expected post-TPE concentration.
The Prognostic Effect of Immune Cell Infiltration Depends on Molecular Subtype in Endometrioid Ovarian Carcinomas
Heinze, Karolin , Cairns, Evan S. , Thornton, Shelby , Harris, Bronwyn , Milne, Katy , Grube, Marcel , Meyer, Charlotte , Karnezis, Anthony N. , Fereday, Sián , Garsed, Dale W. , Leung, Samuel , Harter, Philipp , Bowtell, David D.L. , Goode, Ellen L. , Pike, Malcolm C. , Ramus, Susan J. , Pearce, Celeste Leigh , Staebler, Annette , Kommoss, Stefan , Talhouk, Aline , Anglesio, Michael S. , Leung, Samuel C Y , Chiu, Derek S , Moubarak, Malak , Harter, Philipp , Heitz, Florian , McAlpine, Jessica N , Fazio, Anna de , Bowtell, David D , Goode, Ellen L , Pike, Malcolm C , Ramus, Susan J , Pearce, Celeste Leigh , Staebler, Annette , Köbel, Martin , Kommoss, Stefan , Talhouk, Aline , Nelson, Brad H , Anglesio, Michael S , Karnezis, Anthony , Fereday, Sian , Garsed, Dale W , Milne, Katy , Heitz, Florian , McAlpine, Jessica N. , DeFazio, Anna , Köbel, Martin , Nelson, Brad H.

Mayo Clinic

Clinical Cancer Research | June 20, 2023 | Volume: 29 | Issue: 17 | Pages: 3471-3483

10.1158/1078-0432.ccr-22-3815 | PMID 37339172 Get It

Abstract Purpose: Endometrioid ovarian carcinoma (ENOC) is the second most-common type of ovarian carcinoma, comprising 10%–20% of cases. Recently, the study of ENOC has benefitted from comparisons to endometrial carcinomas including defining ENOC with four prognostic molecular subtypes. Each subtype suggests differential mechanisms of progression, although tumor-initiating events remain elusive. There is evidence that the ovarian microenvironment may be critical to early lesion establishment and progression. However, while immune infiltrates have been well studied in high-grade serous ovarian carcinoma, studies in ENOC are limited. Experimental Design: We report on 210 ENOC, with clinical follow-up and molecular subtype annotation. Using multiplex IHC and immunofluorescence, we examine the prevalence of T-cell lineage, B-cell lineage, macrophages, and populations with programmed cell death protein 1 or programmed death-ligand 1 across subtypes of ENOC. Results: Immune cell infiltrates in tumor epithelium and stroma showed higher densities in ENOC subtypes with known high mutation burden (POLEmut and MMRd). While molecular subtypes were prognostically significant, immune infiltrates were not (overall survival P > 0.2). Analysis by molecular subtype revealed that immune cell density was prognostically significant in only the no specific molecular profile (NSMP) subtype, where immune infiltrates lacking B cells (TILB minus) had inferior outcome (disease-specific survival: HR, 4.0; 95% confidence interval, 1.1–14.7; P < 0.05). Similar to endometrial carcinomas, molecular subtype stratification was generally superior to immune response in predicting outcomes. Conclusions: Subtype stratification is critical for better understanding of ENOC, in particular the distribution and prognostic significance of immune cell infiltrates. The role of B cells in the immune response within NSMP tumors warrants further study.
Safety and Efficacy of Axicabtagene Ciloleucel versus Standard of Care in Patients 65 Years of Age or Older with Relapsed/Refractory Large B-Cell Lymphoma
Westin, Jason R. , Locke, Frederick L. , Dickinson, Michael , Ghobadi, Armin , Elsawy, Mahmoud , Meerten, Tom van , Miklos, David B. , Ulrickson, Matthew L. , Perales, Miguel‐Angel , Farooq, Umar , Leslie, Lori A. , Kersten, Marie José , Jacobson, Caron A. , Pagel, John M. , Wulf, Gerald , Johnston, Patrick B. , Rapoport, Aaron P. , Du, Linqiu , Vardhanabhuti, Saran , Filosto, Simone , Shah, Jina , Snider, Julia Thornton , Cheng, Paul , To, Christina , Oluwole, Olalekan O. , Sureda, Anna , van Meerten, Tom , Wannesson, Luciano , Leslie, Lori , Kersten, Marie José , Jacobson, Caron A , Pagel, John M , Wulf, Gerald , Johnston, Patrick , Rapoport, Aaron P , Du, Linqiu , Vardhanabhuti, Saran , Filosto, Simone , Shah, Jina , Snider, Julia T , Cheng, Paul , To, Christina , Oluwole, Olalekan O , Sureda, Anna , Farooq, Umar , Perales, Miguel-Angel , Miklos, David B , Westin, Jason R , Dickinson, Michael , Ghobadi, Armin , Locke, Frederick L

Mayo Clinic

Clinical Cancer Research | March 31, 2023 | Volume: 29 | Issue: 10 | Pages: 1894-1905

10.1158/1078-0432.ccr-22-3136 | PMID 36999993 Get It

Abstract Purpose: Older patients with relapsed/refractory (R/R) large B-cell lymphoma (LBCL) may be considered ineligible for curative-intent therapy including high-dose chemotherapy with autologous stem-cell transplantation (HDT-ASCT). Here, we report outcomes of a preplanned subgroup analysis of patients ≥65 years in ZUMA-7. Patients and Methods: Patients with LBCL refractory to or relapsed ≤12 months after first-line chemoimmunotherapy were randomized 1:1 to axicabtagene ciloleucel [axi-cel; autologous anti-CD19 chimeric antigen receptor (CAR) T-cell therapy] or standard of care (SOC; 2–3 cycles of chemoimmunotherapy followed by HDT-ASCT). The primary endpoint was event-free survival (EFS). Secondary endpoints included safety and patient-reported outcomes (PROs). Results: Fifty-one and 58 patients aged ≥65 years were randomized to axi-cel and SOC, respectively. Median EFS was greater with axi-cel versus SOC (21.5 vs. 2.5 months; median follow-up: 24.3 months; HR, 0.276; descriptive P < 0.0001). Objective response rate was higher with axi-cel versus SOC (88% vs. 52%; OR, 8.81; descriptive P < 0.0001; complete response rate: 75% vs. 33%). Grade ≥3 adverse events occurred in 94% of axi-cel and 82% of SOC patients. No grade 5 cytokine release syndrome or neurologic events occurred. In the quality-of-life analysis, the mean change in PRO scores from baseline at days 100 and 150 favored axi-cel for EORTC QLQ-C30 Global Health, Physical Functioning, and EQ-5D-5L visual analog scale (descriptive P < 0.05). CAR T-cell expansion and baseline serum inflammatory profile were comparable in patients ≥65 and <65 years. Conclusions: Axi-cel is an effective second-line curative-intent therapy with a manageable safety profile and improved PROs for patients ≥65 years with R/R LBCL.
Association of African Ancestry–Specific APOE Missense Variant R145C With Risk of Alzheimer Disease
Guen, Yann Le , Raulin, Ana‐Caroline , Belloy, Michaël E. , Eger, Sarah J. , Kennedy, Gabriel , Kuchenbecker, Lindsey A. , O’Leary, Justin , Panizzon, Matthew S. , Hauger, Richard L. , Gaziano, J. Michael , Bu, Guojun , Thornton, Timothy A. , He, Zihuai , Greicius, Michael D. , Kuchenbecker, Lindsey, O'Leary, Justin P, Bu, Guojun , Raulin, Ana-Caroline , Le Guen, Yann , Belloy, Michael E , Logue, Mark W. , Sherva, Richard , Chen, Shen‐Hsing Annabel , Zhang, Rui , Merritt, Victoria C. , Hauger, Richard L. , Farrer, Lindsay A. , Napolioni, Valerio

Mayo Clinic

JAMA | February 21, 2023 | Volume: 329 | Issue: 7 | Pages: 551

10.1001/jama.2023.0268 | PMID 36809323 Get It

Importance Numerous studies have established the association of the common APOE ε2 and APOE ε4 alleles with Alzheimer disease (AD) risk across ancestries. Studies of the interaction of these alleles with other amino acid changes on APOE in non-European ancestries are lacking and may improve ancestry-specific risk prediction. Objective To determine whether APOE amino acid changes specific to individuals of African ancestry modulate AD risk. Design, Setting, and Participants Case-control study including 31 929 participants and using a sequenced discovery sample (Alzheimer Disease Sequencing Project; stage 1) followed by 2 microarray imputed data sets derived from the Alzheimer Disease Genetic Consortium (stage 2, internal replication) and the Million Veteran Program (stage 3, external validation). This study combined case-control, family-based, population-based, and longitudinal AD cohorts, which recruited participants (1991-2022) in primarily US-based studies with 1 US/Nigerian study. Across all stages, individuals included in this study were of African ancestry. Exposures Two APOE missense variants (R145C and R150H) were assessed, stratified by APOE genotype. Main Outcomes and Measures The primary outcome was AD case-control status, and secondary outcomes included age at AD onset. Results Stage 1 included 2888 cases (median age, 77 [IQR, 71-83] years; 31.3% male) and 4957 controls (median age, 77 [IQR, 71-83] years; 28.0% male). In stage 2, across multiple cohorts, 1201 cases (median age, 75 [IQR, 69-81] years; 30.8% male) and 2744 controls (median age, 80 [IQR, 75-84] years; 31.4% male) were included. In stage 3, 733 cases (median age, 79.4 [IQR, 73.8-86.5] years; 97.0% male) and 19 406 controls (median age, 71.9 [IQR, 68.4-75.8] years; 94.5% male) were included. In ε3/ε4-stratified analyses of stage 1, R145C was present in 52 individuals with AD (4.8%) and 19 controls (1.5%); R145C was associated with an increased risk of AD (odds ratio [OR], 3.01; 95% CI, 1.87-4.85; P = 6.0 × 10 −6 ) and was associated with a reported younger age at AD onset (β, −5.87 years; 95% CI, −8.35 to −3.4 years; P = 3.4 × 10 −6 ). Association with increased AD risk was replicated in stage 2 (R145C was present in 23 individuals with AD [4.7%] and 21 controls [2.7%]; OR, 2.20; 95% CI, 1.04-4.65; P = .04) and was concordant in stage 3 (R145C was present in 11 individuals with AD [3.8%] and 149 controls [2.7%]; OR, 1.90; 95% CI, 0.99-3.64; P = .051). Association with earlier AD onset was replicated in stage 2 (β, −5.23 years; 95% CI, −9.58 to −0.87 years; P = .02) and stage 3 (β, −10.15 years; 95% CI, −15.66 to −4.64 years; P = 4.0 × 10 −4 ). No significant associations were observed in other APOE strata for R145C or in any APOE strata for R150H. Conclusions and Relevance In this exploratory analysis, the APOE ε3[R145C] missense variant was associated with an increased risk of AD among individuals of African ancestry with the ε3/ε4 genotype. With additional external validation, these findings may inform AD genetic risk assessment in individuals of African ancestry.
Joint Adult and Pediatric Working Group as a Successful Platform to Strengthen Adolescent and Young Adult (AYA) Clinical Trial Collaboration: A Report from the NCTN/SARC AYA Clinical Trials Sarcoma Working Group
Whiteway, Susan L. , Allen‐Rhoades, Wendy , Avutu, Viswatej , Indelicato, Daniel J. , Isakoff, Michael S. , Janeway, Katherine A. , Patel, Shreyaskumar , Riedel, Richard F. , Thornton, Katherine A., Ahmed, Safia K. , Avutu, Viswatej , Reed, Damon R , Riedel, Richard F , Allen-Rhoades, Wendy A , Indelicato, Daniel J , Weiss, Aaron R. , Cardona, Kenneth , Davis, Lara E. , Davis, Elizabeth J. , Livingston, J. Andrew , Reed, Damon R. , Kopp, Lisa M.

Mayo Clinic

Journal of Adolescent and Young Adult Oncology | February 1, 2023 | Volume: 12 | Issue: 5 | Pages: 792-793

10.1089/jayao.2022.0179 | PMID 36724495 Get It

Major Publications in the Critical Care Pharmacotherapy Literature: 2021
Wieruszewski, Patrick M. , Brickett, Laura, Dayal, Lokesh, Egan, Ashley M. , Lemieux, Steven M., Mukkera, Satyanarayana Reddy , Patel, Jaimini, Reichert, Michael, Reynolds, Tessa R. , Thornton, Nathaniel, Turpin, Gavin M., Winter, Jessica , Thornton, Nathaniel M, Wieruszewski, Patrick M , Khanna, Ashish K. , Sen, Parijat , Thornton, Nathaniel M., Bissell, Brittany D.

Mayo Clinic

Critical Care Explorations | December 16, 2022 | Volume: 4 | Issue: 12 | Pages: e0823

10.1097/cce.0000000000000823 | PMID 36567788 Get It

OBJECTIVES: To summarize the most impactful articles relevant to the pharmacotherapy of critically ill adult patients published in 2021. DATA SOURCE: PubMed/MEDLINE. STUDY SELECTION: Randomized controlled trials, prospective studies, or systematic review/meta-analyses of adult critical care patients assessing a pharmacotherapeutic intervention and reporting clinical endpoints published between January 1, 2021, and December 31, 2021. DATA EXTRACTION: Candidate articles were organized by clinical domain based on the emerging themes from all studies. A modified Delphi process was applied to obtain consensus on the most impactful publication within each clinical domain based on overall contribution to scientific knowledge and novelty to the literature. DATA SYNTHESIS: The search revealed 830 articles, of which 766 were excluded leaving 64 candidate articles for the Delphi process. These 64 articles were organized by clinical domain including: emergency/neurology, cardiopulmonary, nephrology/fluids, infectious diseases, metabolic, immunomodulation, and nutrition/gastroenterology. Each domain required the a priori defined three Delphi rounds. The resultant most impactful articles from each domain included five randomized controlled trials and two systematic review/meta-analyses. Topics studied included sedation during mechanical ventilation, anticoagulation in COVID-19, extended infusion beta-lactams, interleukin-6 antagonists in COVID-19, balanced crystalloid resuscitation, vitamin C/thiamine/hydrocortisone in sepsis, and promotility agents during enteral feeding. CONCLUSIONS: This synoptic review provides a summary and perspective of the most impactful articles relevant to the pharmacotherapy of critically ill adults published in 2021.
The double-edged sword of abortion regulations: Decreasing training opportunities while increasing knowledge requirements
Gyuras, Hillary J., Field, Meredith P. , Thornton, Olivia , McGowan, Michelle L. , Bessett, Danielle

Mayo Clinic

Medical Education Online | November 14, 2022 | Volume: 28 | Issue: 1 | Pages: No page available

10.1080/10872981.2022.2145104 | PMID 36373897 Get It